FDA Cloning Oversight Is "Tenuous," May Need Augmentation - Rep. Tauzin
FDA's regulatory authority over reproductive human cloning appears inadequate and should be either bolstered or granted to another federal agency, House Energy & Commerce Committee Chairman Tauzin (R-La.) told a Commerce/Oversight & Investigations Subcommittee hearing on human cloning March 28.
You may also be interested in...
The Bush Administration favors the more restrictive of two House bills to ban human cloning.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011